LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: GPRC5D-Targeted CAR T Cells for Myeloma.

    Mailankody, Sham / Devlin, Sean M / Landa, Jonathan / Nath, Karthik / Diamonte, Claudia / Carstens, Elizabeth J / Russo, Douglas / Auclair, Romany / Fitzgerald, Lisa / Cadzin, Briana / Wang, Xiuyan / Sikder, Devanjan / Senechal, Brigitte / Bermudez, Vladimir P / Purdon, Terence J / Hosszu, Kinga / McAvoy, Devin P / Farzana, Tasmin / Mead, Elena /
    Wilcox, Jessica A / Santomasso, Bianca D / Shah, Gunjan L / Shah, Urvi A / Korde, Neha / Lesokhin, Alexander / Tan, Carlyn R / Hultcrantz, Malin / Hassoun, Hani / Roshal, Mikhail / Sen, Filiz / Dogan, Ahmet / Landgren, Ola / Giralt, Sergio A / Park, Jae H / Usmani, Saad Z / Rivière, Isabelle / Brentjens, Renier J / Smith, Eric L

    The New England journal of medicine

    2022  Volume 387, Issue 13, Page(s) 1196–1206

    Abstract: Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) ... ...

    Abstract Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) has been identified as an immunotherapeutic target in multiple myeloma. Preclinical studies have shown the efficacy of GPRC5D-targeted CAR T cells, including activity in a BCMA antigen escape model.
    Methods: In this phase 1 dose-escalation study, we administered a GPRC5D-targeted CAR T-cell therapy (MCARH109) at four dose levels to patients with heavily pretreated multiple myeloma, including patients with relapse after BCMA CAR T-cell therapy.
    Results: A total of 17 patients were enrolled and received MCARH109 therapy. The maximum tolerated dose was identified at 150×10
    Conclusions: The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04555551.).
    MeSH term(s) B-Cell Maturation Antigen/therapeutic use ; Cytokine Release Syndrome/etiology ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local/etiology ; Receptors, Chimeric Antigen/therapeutic use ; Receptors, G-Protein-Coupled/therapeutic use ; T-Lymphocytes
    Chemical Substances B-Cell Maturation Antigen ; GPRC5D protein, human ; Receptors, Chimeric Antigen ; Receptors, G-Protein-Coupled
    Language English
    Publishing date 2022-06-21
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2209900
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

    Moskowitz, Alison J / Schöder, Heiko / Gavane, Somali / Thoren, Katie L / Fleisher, Martin / Yahalom, Joachim / McCall, Susan J / Cadzin, Briana R / Fox, Stephanie Y / Gerecitano, John / Grewal, Ravinder / Hamlin, Paul A / Horwitz, Steven M / Kumar, Anita / Matasar, Matthew / Ni, Andy / Noy, Ariela / Palomba, M Lia / Perales, Miguel-Angel /
    Portlock, Carol S / Sauter, Craig / Straus, David / Younes, Anas / Zelenetz, Andrew D / Moskowitz, Craig H

    Blood

    2017  Volume 130, Issue 20, Page(s) 2196–2203

    Abstract: Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study of positron emission tomography (PET)-adapted salvage therapy with ... ...

    Abstract Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study of positron emission tomography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinical factors, quantitative PET assessments, and cytokine and chemokine values. Transplant-eligible patients with relapsed/refractory HL received 2 (cohort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative patients (Deauville score ≤2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive patients received augICE before ASCT. Serum cytokine and chemokine levels were measured at baseline and after BV. Metabolic tumor volume (MTV) and total lesion glycolysis were measured at baseline, after BV, and after augICE. Sixty-five patients enrolled (45, cohort 1; 20, cohort 2); 49 (75%) achieved complete response and 64 proceeded to ASCT. Three-year overall survival and event-free survival (EFS) were 95% and 82%, respectively. Factors predictive for EFS by multivariable analysis were baseline MTV (bMTV) (
    MeSH term(s) Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brentuximab Vedotin ; Carboplatin/therapeutic use ; Chemokines/blood ; Chemokines/drug effects ; Cytokines/blood ; Cytokines/drug effects ; Disease-Free Survival ; Etoposide/therapeutic use ; Female ; Hodgkin Disease/diagnosis ; Hodgkin Disease/mortality ; Hodgkin Disease/therapy ; Humans ; Ifosfamide/therapeutic use ; Immunoconjugates/therapeutic use ; Male ; Middle Aged ; Positron-Emission Tomography ; Prognosis ; Salvage Therapy/methods ; Stem Cell Transplantation/methods ; Transplantation, Autologous ; Tumor Burden ; Young Adult
    Chemical Substances Chemokines ; Cytokines ; Immunoconjugates ; Etoposide (6PLQ3CP4P3) ; Brentuximab Vedotin (7XL5ISS668) ; Carboplatin (BG3F62OND5) ; Ifosfamide (UM20QQM95Y)
    Language English
    Publishing date 2017-09-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2017-06-788877
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top